Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma

  • Autophagy. 2022 Sep 7;1-15. doi: 10.1080/15548627.2022.2117893.
Jiaomeng Pan  1 ,  Mao Zhang  1 ,  Liangqing Dong  1 ,  Shuyi Ji  2 ,  Juan Zhang  1 ,  Shu Zhang  1 ,  Youpei Lin  1 ,  Xiaoying Wang  1 ,  Zhenbin Ding  1 ,  Shuangjian Qiu  1 ,  Daming Gao  3 ,  Jian Zhou  1 ,  Jia Fan  1  4  5 ,  Qiang Gao  1  4  5
Affiliations
  • 1. Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, China.
  • 2. Center for Tumor Diagnosis & Therapy, Jinshan Hospital, Fudan University, Shanghai, China.
  • 3. State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China.
  • 4. Institute of Biomedical Sciences, Fudan University, Shanghai, China.
  • 5. State Key Laboratory of Genetic Engineering, Fudan University, Shanghai, China.
PMID: 36037300 DOI: 10.1080/15548627.2022.2117893
Abstract

cld-CASP3: cleaved Caspase 3; cld-PARP: cleaved PARP; DTP: drug tolerant persister; GO: Gene Ontology; GTEx: The Genotype-Tissue Expression; HCC: hepatocellular carcinoma; HCQ: hydroxychloroquine; IC50: half maximal inhibitory concentration value; KEGG: Kyoto Encyclopedia of Genes and Genomes; LAPTM5: lysosomal protein transmembrane 5; NT: non-targeting; PDC: patient-derived primary cell lines; PDO: patient-derived primary organoid; TCGA: The Cancer Genome Atlas.

Keywords
Autophagy; LAPTM5; drug resistance; lenvatinib; liver cancer; whole-genome CRISPR-Cas9 screen.
Products